There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alpha Cognition Inc (ACOG) and Travere Therapeutics (TVTX) with bullish sentiments. According to TipRanks ...

This is a real growth story, and FILSPARI is now the only approved medicine in its younger indication. But I rate the shares a Hold at this price. The valuation has run ahead of the evidence: roughly ...

New grant program supporting innovations in early detection and accurate diagnosis of kidney failure to be announced at summit ...

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that it will share nine new data presentations, including five oral presentations, at the American Society of Nephrology (ASN) Kidney Week ...

Travere Therapeutics (Nasdaq: TVTX) plans to present nine data sets, including five oral presentations, on its drug Filspari (sparsentan) at the American Society of Nephrology Kidney Week 2026 in ...

Today, the American Kidney Fund (AKF) and the IgA Nephropathy Foundation are on Capitol Hill with more than 80 advocates who are living with rare kidney diseases to urge elected officials to support ...

Summary:The company released its 2026 interim report, reporting revenue of RMB 1.148 billion for the first half of 2026, up ...

Discover why Travere Therapeutics Inc's stock is sliding today, with insights into its recent patent news and leadership ...

On Dec. 1, Travere Therapeutics will have a new CEO for the first time in almost eight years, as Eric Dube hands the baton to ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Discover the latest updates on Baytex Energy Corp stock, including performance metrics, analyst outlooks, and key company ...

Novartis gained approval of a drug in IgAN with the same target as Roche’s sefaxersen in 2026.